HC Wainwright Has Bullish Forecast for ALLO FY2025 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Research analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of Allogene Therapeutics in a research report issued on Monday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.93) per share for the year, up from their previous estimate of ($1.06). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q4 2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($1.01) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04.

ALLO has been the topic of a number of other reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Wall Street Zen cut Allogene Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, October 12th. JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allogene Therapeutics in a research note on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44.

Allogene Therapeutics Price Performance

Shares of Allogene Therapeutics stock opened at $1.24 on Wednesday. Allogene Therapeutics has a 1-year low of $0.86 and a 1-year high of $3.78. The company’s fifty day simple moving average is $1.22 and its 200-day simple moving average is $1.23. The stock has a market capitalization of $278.67 million, a PE ratio of -1.27 and a beta of 0.42.

Insider Activity at Allogene Therapeutics

In other news, CFO Geoffrey M. Parker sold 36,744 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The stock was sold at an average price of $1.26, for a total transaction of $46,297.44. Following the transaction, the chief financial officer owned 1,276,796 shares of the company’s stock, valued at approximately $1,608,762.96. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 13.20% of the company’s stock.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd lifted its holdings in shares of Allogene Therapeutics by 88.8% in the 3rd quarter. R Squared Ltd now owns 61,373 shares of the company’s stock worth $76,000 after buying an additional 28,860 shares during the period. Primecap Management Co. CA raised its holdings in shares of Allogene Therapeutics by 23.8% in the third quarter. Primecap Management Co. CA now owns 7,079,308 shares of the company’s stock valued at $8,778,000 after acquiring an additional 1,360,168 shares in the last quarter. Patient Square Capital LP lifted its stake in Allogene Therapeutics by 13.1% in the third quarter. Patient Square Capital LP now owns 2,981,396 shares of the company’s stock worth $3,697,000 after acquiring an additional 346,396 shares during the period. Harold Davidson & Associates Inc. grew its holdings in Allogene Therapeutics by 118.5% during the 3rd quarter. Harold Davidson & Associates Inc. now owns 295,432 shares of the company’s stock worth $366,000 after acquiring an additional 160,204 shares in the last quarter. Finally, Levin Capital Strategies L.P. purchased a new position in Allogene Therapeutics during the 3rd quarter valued at about $65,000. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).